China's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.
Jon Zifferblatt
Advertisement
Articles by Jon Zifferblatt
Advertisement
Latest Updated Articles
Preparing For the New ChinaFebruary 23rd 2012
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5